Search Icon
SCYNEXIS, Inc. (NASDAQ:SCYX) - Pioneering Innovative Medicines to Overcome Drug-Resistant Infections
Published on September 24, 2024 | Ticker: SCYX

SCYNEXIS, Inc. is a biotechnology company headquartered in Jersey City, New Jersey, that is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its proprietary class of enfumafungin-derived antifungal compounds ("fungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications.

Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the "fungerp" family, including SCY-247, in preclinical stages of development. In June 2021 and December 2022, the U.S. Food and Drug Administration (FDA) approved BREXAFEMME (ibrexafungerp tablets) for the treatment of patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.

Business Overview

SCYNEXIS is developing ibrexafungerp, an oral antifungal agent, for the treatment of various fungal infections, including VVC, invasive candidiasis (IC), and invasive aspergillosis (IA). The company's pipeline also includes SCY-247, a second-generation antifungal compound from the "fungerp" class, which is in preclinical development.

The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to ibrexafungerp for the indications of VVC (including the prevention of recurrent VVC), IC (including candidemia), and IA. The company has also received Orphan Drug designations for the IC and IA indications from the FDA. These designations may provide SCYNEXIS with additional market exclusivity and expedited regulatory paths.

In March 2023, SCYNEXIS entered into a license agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK), granting GSK an exclusive, royalty-bearing, sublicensable license for the development and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications in all countries outside of Greater China and certain other countries already licensed to third parties.

Product Recall and Clinical Hold

Following a review by GSK of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, SCYNEXIS became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. As a result, the company has recalled BREXAFEMME (ibrexafungerp tablets) from the market and placed a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study.

The patient-level and clinical product recall is ongoing, and the company is working with an experienced vendor to manage the process. In September 2023, the FDA concurred with SCYNEXIS's voluntary hold and placed a clinical hold. The company is working with the FDA to discuss paths for resolution of this issue. The clinical hold and recall affect the company's two ongoing clinical studies: the Phase 3 MARIO study and a Phase 1 lactation study. The hold does not impact the recently completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies, for which dosing is complete.

Financials

For the full year 2023, SCYNEXIS reported annual net income of $67,041,000, annual revenue of $140,141,000, annual operating cash flow of $60,159,000, and annual free cash flow of $60,159,000.

For the first quarter of 2024, the company reported revenue of $1,373,000, which consisted of $1,373,000 in license agreement revenue associated with the GSK License Agreement. This represents a 21.5% increase compared to the first quarter of 2023, when the company reported revenue of $1,130,000 from product sales of BREXAFEMME.

The company's research and development expenses for the first quarter of 2024 were $7,212,000, compared to $6,835,000 in the first quarter of 2023, an increase of 5.5%. This increase was primarily driven by higher chemistry, manufacturing, and controls (CMC) expenses and preclinical expenses, partially offset by lower clinical expenses and salaries.

Selling, general, and administrative expenses for the first quarter of 2024 were $3,669,000, down 24.2% from $4,840,000 in the first quarter of 2023. The decrease was primarily due to lower professional fees and commercial expenses.

For the first quarter of 2024, SCYNEXIS reported net income of $411,000, compared to a net loss of $33,876,000 in the first quarter of 2023. The improvement in net income was primarily driven by a gain of $9,608,000 on the fair value adjustment of the warrant liabilities, compared to a loss of $21,673,000 in the prior-year period.

Liquidity

As of March 31, 2024, SCYNEXIS had cash, cash equivalents, and investments of $94,187,000, compared to $98,006,000 as of December 31, 2023. The company believes its capital resources are sufficient to fund its ongoing operations for at least the next 12 months.

SCYNEXIS's liquidity could be materially affected by several factors, including its ability to raise additional capital, costs associated with new or existing strategic alliances or licensing and collaboration arrangements, negative regulatory events or unanticipated costs related to the development of ibrexafungerp, and its ability to achieve the development, regulatory, and commercial milestones under the License Agreement with GSK.

Risks and Challenges

The company faces several risks, including the successful resolution of the clinical hold and product recall, the ability to obtain regulatory approvals for ibrexafungerp and SCY-247, the successful commercialization of its products, and the ability to secure additional funding to support its ongoing operations and development activities.

Outlook

Despite the current challenges, SCYNEXIS remains focused on advancing its pipeline of antifungal compounds, including ibrexafungerp and SCY-247, to address the growing threat of drug-resistant fungal infections. The company is working closely with the FDA to resolve the clinical hold and resume its development activities. Additionally, the License Agreement with GSK provides SCYNEXIS with the potential for significant milestone payments and royalties, which could strengthen the company's financial position going forward.

Conclusion

SCYNEXIS is a biotechnology company that is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The company's lead product, ibrexafungerp, has been approved by the FDA for the treatment of VVC and RVVC, and the company is working to advance its pipeline of antifungal compounds, including SCY-247, to address the growing threat of fungal infections.

While the company is currently facing challenges related to a product recall and clinical hold, SCYNEXIS remains focused on resolving these issues and continuing the development of its promising antifungal candidates. The company's strong financial position, with $94,187,000 in cash, cash equivalents, and investments as of March 31, 2024, and the potential for significant milestone payments and royalties from the GSK License Agreement, provide a solid foundation for the company's future growth and development.

You may be interested in...
Vaxart (VXRT): A Trailblazer in Oral Vaccine Innovation
Vaxart, Inc. (VXRT) is a clinical-stage biotechnology company leading the charge in developing a transformative oral vaccine platform. With a diverse pipeline targeting major infectious diseases and a steadfast commitment to improving global public health, Vaxart has emerged as a pioneering force in the pharmaceutical industry.
Read More
Pioneering Innovative Medicines at SCYNEXIS (SCYX)
SCYNEXIS, Inc. (SCYX) is a biotechnology company at the forefront of developing novel antifungal agents to overcome and prevent difficult-to-treat and drug-resistant infections. With a focus on the proprietary class of antifungal compounds called fungerps, SCYNEXIS is paving the way for innovative solutions to address the growing challenge of fungal infections.
Read More
Chimerix (CMRX): Advancing Novel Therapies for Deadly Diseases
Chimerix, a biopharmaceutical company, is dedicated to developing medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus on oncology, the company's pipeline includes its lead asset, dordaviprone (ONC201), and a second-generation compound, ONC206, both targeting critical unmet needs.
Read More
VYNE Therapeutics (NASDAQ:VYNE): Pioneering Breakthrough Therapies for Chronic Inflammatory Conditions
VYNE Therapeutics is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapies to address the significant unmet needs of patients suffering from chronic inflammatory and immune-mediated conditions. Through its proprietary InhiBET™ platform, VYNE is pioneering the use of selective bromodomain and extra-terminal (BET) inhibitors, a novel class of therapeutics with immense potential in the field of immuno-inflammatory diseases.
Read More
Enanta Pharmaceuticals (ENTA): A Promising Biotech Navigating Challenges and Opportunities
Enanta Pharmaceuticals, Inc. (ENTA) is a clinical-stage biotechnology company that has established itself as a leader in the development of small molecule drugs for virology and immunology indications. The company’s robust pipeline and innovative approach to drug discovery have positioned it as a promising player in the dynamic pharmaceutical landscape.
Read More